Latest return on equity
Halozyme Therapeutics Return on equity
Direct answer
Halozyme Therapeutics's return on equity is 173.67%.
The verified market snapshot reports 173.67%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked September 27, 2026.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Return on equity
- 173.67%
Explore related company data
View Halozyme Therapeutics's market capitalizationView Halozyme Therapeutics's p/e ratioView Halozyme Therapeutics's price-to-book ratioView Halozyme Therapeutics's 52-week price rangeView Halozyme Therapeutics's revenue growthView Halozyme Therapeutics's profit marginView Halozyme Therapeutics's debt-to-equity ratioView all Halozyme Therapeutics key metricsReturn to Halozyme Therapeutics profile